
ADVERTISING 2018

RealRate

US-China Biomedical Technology Inc. Rank 27 of 27







ADVERTISING 2018

US-China Biomedical Technology Inc. Rank 27 of 27

The relative strengths and weaknesses of US-China Biomedical Technology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of US-China Biomedical Technology Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 922% points. The greatest weakness of US-China Biomedical Technology Inc. is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 2,485% points.

The company's Economic Capital Ratio, given in the ranking table, is -3,125%, being 2,579% points below the market average of -546%.

Input Variable	Value in 1000 USD
Assets, Current	0
Assets, Non-Current	0
Cost of Goods and Services Sold	0
General and Administrative Expense	44
Intangible Assets	0
Liabilities, Current	14
Liabilities, Non-Current	0
Marketing and Selling Expenses	0
Other Assets	6.0
Other Compr. Net Income	0
Other Expenses	0.80
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property, Plant and Equipment	0

Output Variable	Value in 1000 USD
Assets	6.0
Liabilities	14
Expenses	45
Revenues	0
Stockholders Equity	-8.1
Net Income	-45
Comprehensive Net Income	-45
Economic Capital Ratio	-3,125%

